GenSight Biologics S.A. (EPA:SIGHT)
France
· Delayed Price · Currency is EUR 0.0814
0.00 (0.00%)
Apr 28, 2026, 5:35 PM CET
GenSight Biologics Employees
GenSight Biologics had 16 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
16
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€50,154
Profits / Employee
€925,846
Market Cap
19.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Advicenne | 13 |
| Aelis Farma | 24 |
| Aton | 9 |
| genOway Société anonyme | 148 |
| Poxel | 5 |
| NFL Biosciences | 5 |
| Nicox | 5 |
| Plant Advanced Technologies | 16 |
GenSight Biologics News
- 13 days ago - GenSight Biologics Announces the Filing of its 2025 Universal Registration Document - Business Wire
- 21 days ago - GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026 - Business Wire
- 25 days ago - GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates - Business Wire
- 4 weeks ago - GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025 - Business Wire
- 5 weeks ago - The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® - Business Wire
- 7 weeks ago - GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study - Business Wire
- 2 months ago - GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments - Business Wire
- 2 months ago - The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study - Business Wire